Page last updated: 2024-08-21

indazoles and niraparib

indazoles has been researched along with niraparib in 173 studies

Research

Studies (173)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (0.58)	29.6817
2010's	73 (42.20)	24.3611
2020's	99 (57.23)	2.80

Authors

Authors	Studies
Altamura, S; Boueres, J; Ferrigno, F; Fonsi, M; Giomini, C; Jones, P; Lamartina, S; Monteagudo, E; Ontoria, JM; Orsale, MV; Palumbi, MC; Pesci, S; Roscilli, G; Rowley, M; Scarpelli, R; Schultz-Fademrecht, C; Toniatti, C	1
Ang, KK; Buchholz, T; Buser-Doepner, C; Mason, KA; Mathur, A; Milas, L; Toniatti, C; Valdecanas, D; Wang, L	1
Bhargava, S; Chen, J; Haas-Kogan, DA; Kolkowitz, I; Matthay, KK; Molinaro, AM; Mueller, S; Olow, A; Orbach, S; Wehmeijer, N; Yang, X	1
Baird, RD; Carpenter, CL; Chatterjee, M; de Bono, JS; Forster, M; Gevensleben, H; Hylands, L; Iannone, R; Kaye, SB; Kreischer, N; Loughney, J; Miranda, S; Moreno, V; Omlin, A; Riisnaes, R; Sandhu, SK; Schelman, WR; Sun, L; Thway, K; Toniatti, C; Wenham, RM; Wilding, G	1
Burris, HA; Infante, JR	1
André, F; Ashworth, A; Bajrami, I; Dorvault, N; Elliott, R; Fontebasso, Y; Friboulet, L; Lord, CJ; Olaussen, KA; Postel-Vinay, S; Soria, JC	1
Konstantinopoulos, PA; Liu, JF; Matulonis, UA	1
Bridges, KA; Buchholz, TA; Buser, CA; Liu, H; Meyn, RE; Toniatti, C	1
Jones, P; Rowley, M; Toniatti, C; Wilcoxen, K	1
DiGiammarino, EL; Donawho, CK; Gao, W; Hopkins, TA; Johnson, EF; Maag, D; Olson, AM; Osterling, DJ; Panchal, SC; Rodriguez, LE; Shi, Y; Solomon, LR; Stolarik, DF; Wilsbacher, JL	1
Seimiya, H	1
Agnihotri, S; Buczkowicz, P; Chornenkyy, Y; Dirks, PB; Garzia, L; Golbourn, B; Hawkins, C; Leung, S; Rakopoulos, P; Rutka, JT; Siddaway, R; Taylor, MD; Yu, M	1
Mullard, A	1
AlHilli, MM; Becker, MA; Flatten, KS; Haluska, P; Harrell, MI; Harrington, SC; Hawthorne, KM; Hou, X; Hurley, RM; Kalli, KR; Kaufmann, SH; Maurer, MJ; McKinstry, S; Meng, XW; Oberg, AL; Swisher, EM; Weroha, SJ; Wilcoxen, KM	1
Agarwal, S; Balser, JP; Ben-Baruch, NE; Benigno, B; Berek, JS; Buscema, J; Christensen, RD; du Bois, A; Dørum, A; Fabbro, M; Follana, P; Gilbert, L; González-Martín, A; Herrstedt, J; Ledermann, JA; Lorusso, D; Mądry, R; Mahner, S; Marth, C; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Redondo, A; Rimel, BJ; Rosenberg, P; Tinker, AV; Vergote, I	1
Agarwal, S; Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Lu, S; Rosing, H; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z	1
Cohen, MS; Ekblad, T; Karlberg, T; Löw, M; Moche, M; Pinto, AF; Schüler, H; Thorsell, AG; Trésaugues, L	1
Scott, LJ	1
Lorusso, D; Sabatucci, I	1
George, TJ; Hromas, R; Jaiswal, AS; Jones, D; Najmunnisa, N; Sidhu, GS; Srinivasan, G; Wilcoxen, K; Williamson, EA	1
Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Rosing, H; Sanghvi, M; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z	1
Agarwal, S; Burris, H; Kansra, V; Moore, K; Patel, MR; Zhang, ZY	1
Matulonis, UA; Mirza, MR; Moore, KN	1
Avogadri-Connors, F; Booth, L; Cutler, RE; Dent, P; Lalani, AS; Poklepovic, A; Roberts, JL; Samuel, P	1
Longoria, TC; Tewari, KS	1
Gillard, M; Lee, JM; Lipkowitz, S; Zimmer, AS	1
Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L	1
Mountzios, G; Papadimitriou, CA; Papadimitriou, M	1
Berek, JS; Berton-Rigaud, D; Colombo, N; Ellard, S; Ghatage, P; Gonzalez-Martin, A; Guo, W; Hazard, S; Ledermann, J; Lesoin, A; Madry, R; Mahner, S; Matulonis, UA; Mirza, MR; Peen, U; Pineda, M; Redondo, A; Reinthaller, A; Rosengarten, O; Sehouli, J; Vergote, I	1
Lorusso, D; Pignata, S	1
Domchek, SM	1
Ethier, JL; Lheureux, S; Oza, AM	1
Konstantinopoulos, PA; Matulonis, UA	1
Essel, KG; Moore, KN	1
Booth, L; Dent, P; Poklepovic, A; Rais, R; Roberts, JL	1
Agarwal, S; Banerjee, S; Benigno, B; Berek, JS; Berton-Rigaud, D; Buscema, J; D'Hondt, V; Del Campo, JM; Hilpert, F; Hudgens, S; Lund, B; Malander, S; Matulonis, UA; Mirza, MR; Oza, AM; Provencher, D; Scambia, G; Sehouli, J; Tinker, AV; Vázquez, IP	1
Aoki, D; Chiyoda, T	1
Duggan, ST; Heo, YA	1
O'Cearbhaill, RE	1
Gan, N; Li, H; Sun, Q; Tang, P; Wu, D; Xie, T; Zhang, Y	1
Monga, DK; Patibandla, NS	1
Al-Kawaz, A; Ali, R; Band, V; Green, AR; Madhusudan, S; Mesquita, KA; Miligy, IM; Mirza, S; Rakha, EA; Seedhouse, C; Toss, MS	1
Baldini, C; Banerjee, S; Battisti, NML; Dumas, L; Kadambi, S; Lichtman, SM; Liposits, G; Loh, KP; Soto-Perez-de-Celis, E	1
Berta, K; Csabai, I; Klus, GT; Mikule, K; Pipek, O; Póti, Á; Ried, T; Szallasi, Z; Szüts, D; Wilcoxen, K; Xiao, Y	1
Fisher, M; Guy, H; Walder, L	2
Nugent, E; Smith, JA; Tomasino, T; Tran, AT; Zhong, L	1
Wu, L; Zhong, L	1
Coleman, RL; Kurnit, KC; Westin, SN	1
Banerjee, S; Bover, I; Dørum, A; Fabbro, M; Follana, P; Goffin, F; Harter, P; Hazard, SJ; Hellman, K; Mahner, S; Matulonis, UA; Mirza, MR; Moore, KN; Pineda, MJ; Provencher, D; Shapira-Frommer, R; Tinker, AV; Tognon, G; Vázquez, IP; Wenham, RM	1
Bai, H; Jiang, X; Li, W; Li, X; Zhang, Z	1
Callahan, T; Chan, JK; Guo, W; Moore, K; Patel, MR; Secord, AA; Zhang, ZY	1
Federico, L; Feng, B; Feng, N; Hanke, J; Ma, X; Marszalek, JR; Mikule, K; Mills, GB; Ramaswamy, S; Sun, K; Vellano, CP; Wang, J; Wang, Z; Xiao, Y	1
Cohn, DE; Ehrisman, JA; Foote, JR; Havrilesky, LJ; Jewell, E; Liang, MI; Secord, AA	1
Azodi, M; Berek, JS; Chan, JK; Cloven, N; Cristea, M; DiSilvestro, P; Fleming, GF; Geller, MA; Li, Y; Luptakova, K; Matei, DE; Matulonis, UA; Miller, DS; Monk, BJ; Moore, KN; Oza, AM; Rimel, BJ; Secord, AA; Sun, K; Wahner Hendrickson, AE	1
Fagotti, A; Marchetti, C; Scambia, G	1
Campbell, JD; Chapman, RH; Kumar, VM; McQueen, RB; Whittington, MD	1
Bedel, J; Cameron, T; Goble, S; Isaacson, J; Maloney, L; Wallace, K	1
Arora, S; Benigno, B; Berek, JS; Canzler, U; Del Campo, JM; Follana, P; Gil-Martin, M; Gilbert, L; Hazard, SJ; Lesoin, A; Lund, B; Mahner, S; Malander, S; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Provencher, D; Waters, J; Wenham, RM; Woie, K	1
Chen, W; Fan, J; Fu, X; Gao, H; Han, Y; Jin, X; Ju, D; Liu, H; Luan, J; Tang, S; Wu, Z; Zai, W; Zhang, X	1
Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; de Bono, JS; Kaye, SB; Lord, CJ; Mateo, J; Oaknin, A; Serra, V; Tutt, A	1
Aguilera, J; Behbakht, K; Bitler, BG; Brennecke, EP; Cittelly, DM; Ferguson, R; Joglar, AM; Kim, H; McMellen, A; Moldovan, GL; Nurmemmedov, E; Sikora, MJ; Thakar, T; Watson, ZL; Wilson, H; Yamamoto, TM	1
Åvall-Lundqvist, E; Bergmann, TK; Birrer, MJ; Bjørge, L; Brøsen, K; Christensen, RD; Jørgensen, M; Lassen, U; Mäenpää, J; Malander, S; Mau-Sørensen, M; Mirza, MR; Nielsen, F; Roed, H	1
Gao, Y; Hei, Y; Hou, J; Ji, D; Li, W; Lou, G; Milton, A; Wang, D; Wang, W; Wu, X; Xia, B; Yan, J; Yin, R; Zhang, J; Zhang, ZY; Zheng, H	1
Gray, S; Khor, XY; Yiannakis, D	1
Schorge, JO	1
Anttila, M; Åvall Lundqvist, E; Birrer, MJ; Bjørge, L; dePont Christensen, R; Dimoula, M; Hietanen, S; Krog Vistisen, A; Lindahl, G; Lund, B; Mäenpää, JU; Malander, S; Mirza, MR; Nyvang, GB; Peen, U; Roed, H; Staff, S; Werner, TL; Ør Knudsen, A	1
Banerjee, S; Benigno, B; Bessette, P; Buscema, J; Casado Herraez, A; Gil-Martin, M; Guy, H; Hardy-Bessard, AC; Kalbacher, E; Lau, S; Ledermann, JA; Lindahl, G; Mahner, S; Marmé, F; Matulonis, UA; Mirza, MR; Nøttrup, TJ; Travers, K; Walder, L; Wenham, RM; Woie, K	1
Fletcher, SP; Goetzke, FW; González, J; van Dijk, L	1
Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y	1
Backes, F; Barretina-Ginesta, P; Baumann, K; Bradley, WH; Bruchim, I; DePont Christensen, R; Freyer, G; González-Martín, A; Graybill, W; Gupta, D; Haggerty, AF; Hoskins, P; Jardon, K; Li, Y; Lorusso, D; Lund, B; Malinowska, IA; Mangili, G; McCormick, C; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Rubio-Pérez, MJ; Shahin, MS; Sun, K; Vergote, I; Vulsteke, C	1
Gourd, E	1
Ji, Y; Li, L; Sun, G; Wang, Q; Ye, L; Zhao, Q; Zhao, S	1
Amaravadi, RK; Bast, RC; Becker, SE; Heinzen, EP; Hou, X; Llombart-Cussac, A; Lu, Z; Matias-Guiu, X; Maurer, MJ; Oberg, AL; Pang, L; Poveda, A; Rask, P; Romero, I; Rubio, MJ; Santacana, M; Santiago-O'Farrill, JM; Weroha, SJ	1
Long, X; Zhou, Q; Zou, D	1
Walsh, CS	1
Longo, DL	1
Konstantinopoulos, PA; Vinayak, S	1
Lin, J; Yang, X; Zhao, H	1
Rodrigues, M	1
Al-Lazikani, B; Ameratunga, M; Antolin, AA; Banerji, U; Clarke, PA; Workman, P	1
Bridges, KA; Clump, DA; Faust, AZ; Ferris, RL; Frederick, MJ; Heffernan, TP; Mason, KA; Meyn, RE; Molkentine, DP; Molkentine, JM; Myers, JN; Pickering, CR; Sheth, A; Skinner, HD; Xie, T; Yang, L	1
Bhatti, A; Horton, ER; Kerliu, L; Myruski, S; Pervanas, HC; Petrosius, P; Soni, P	1
Bai, J; Kristeleit, R; Monk, BJ; Moore, KN; Tewari, KS; Wolford, JE	1
Casado, J; Chen, YA; Chowdhury, D; D'Andrea, AD; Dezube, BJ; Färkkilä, A; Garcia, E; Graham, JR; Gulhan, DC; Hautaniemi, S; Jacobson, CA; Kochupurakkal, B; Konstantinopoulos, PA; Lako, A; Maliga, Z; Matulonis, UA; Munster, P; Nguyen, H; Park, PJ; Rodig, S; Santagata, S; Schapiro, D; Shapiro, GI; Sorger, PK; Swisher, EM; Yapp, C; Zhou, Y	1
da Costa, A	1
Carter, Z; Jewett, BE; Ligon, LA; Miller, MN; Mohammad, I; Ordway, GA	1
Ai, Z; Bao, W; Chen, X; Feng, Y; Gao, W; Huang, H; Jia, H; Jiang, R; Jiang, W; Li, J; Li, Y; Liu, J; Luan, Y; Shi, T; Teng, Y; Wang, X; Wu, S; Yin, S; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y	1
Cao, J; Chen, M; Frank, SJ; Jiang, B; Li, Y; Lin, E; Myers, JN; Sahoo, N; Wang, L; Wang, X; Wang, Z; Zhang, R; Zhang, X; Zhu, XR	1
Dang, TT; Morales, JC	1
Ayari, H; Boissier, E; Cohen, R; Combe, P; Courbebaisse, M; Crespel, C; Delanoy, N; Karras, A; Lazareth, H; Mercadier-Riaz, E; Pallet, N; Thervet, E	1
Barrington, DA; Cohn, DE; Senter, L; Smith, HJ; Straughn, JM; Tubbs, C	1
Distel, LV; Fietkau, R; Hecht, M; Heinzerling, L; Jost, T; Knippertz, I; Weigert, V	1
Chase, DM; Eakin, CM; Ewongwo, A; Monk, BJ; Pendleton, L	1
Coleman, RL; Onstad, M; Westin, SN	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Dockery, L; Moore, K; Randall, LM; Rimel, BJ	1
Estes, VM; Langelier, MF; Lee, BJ; Lin, X; Pascal, JM; Rouleau-Turcotte, É; Shao, Z; Zha, S	1
Arizio, F; Bironzo, P; Listì, A; Novello, S; Passiglia, F; Righi, L; Scagliotti, GV; Volante, M	1
Barceló, IB; Benigno, B; Berton-Rigaud, D; Bessette, P; Buscema, J; de Jong, FA; du Bois, A; Dørum, A; Gupta, D; Herráez, AC; Herrstedt, J; Kalbacher, E; Lau, S; Ledermann, JA; Levy, T; Lorusso, D; Mahner, S; Matulonis, UA; Mirza, MR; Rimel, BJ; Vergote, I; Wang, P	1
Aragón, IM; Castro, E; Cattrini, C; Cendón, Y; López-Casas, PP; Lozano, R; Olmos, D	1
Gabrail, N; Smith, C	1
Penn, CA; Walsh, CS; Wong, MS	1
Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T	1
Aoki, D; Hamanishi, J; Harano, K; Hasegawa, K; Hirasawa, T; Hori, K; Kase, Y; Komiyama, S; Kondo, E; Matsuura, M; Nakai, H; Nakamura, H; Nakamura, T; Okamoto, A; Sakata, J; Soeda, J; Sugiyama, T; Sumino, S; Suri, A; Tabata, T; Takehara, K; Takekuma, M; Yanagida, S; Yokoyama, Y	1
Belli, V; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; Della Corte, C; Desiderio, V; Giunta, EF; Martinelli, E; Martini, G; Matrone, N; Mele, L; Morgillo, F; Napolitano, S; Papaccio, G; Poliero, L; Selvaggi, F; Tirino, V; Troiani, T; Vitiello, PP	1
Abulizi, G; An, RF; Chen, LP; Chen, QH; Cui, H; Gao, YN; Hao, M; Hou, JM; Huang, XH; Huang, Y; Kong, BH; Li, GL; Liu, JH; Liu, ZL; Lou, G; Lu, WG; Lu, X; Mirza, MR; Tian, XF; Wang, DB; Wang, J; Wang, K; Wang, L; Wen, H; Wu, LY; Wu, XH; Yan, XJ; Yang, HY; Yang, JX; Yin, RT; Zhang, C; Zhang, Y; Zhou, Q; Zhu, JQ	1
Hamanishi, J; Hasegawa, K; Itamochi, H; Kase, Y; Matsumoto, T; Matsuura, M; Miura, K; Nagao, S; Nakai, H; Sumino, S; Suri, A; Takehara, K; Takeshima, N; Tanaka, N; Tokunaga, H; Ushijima, K; Watari, H; Yokoyama, Y	1
Grewal, K; Tabbara, IA	1
Luger, K; Roberts, G; Rudolph, J	1
Gao, H; Wang, Q; Xu, Y; Zhang, F	1
Hong, SH	1
Iwasa, S; Kase, Y; Kitano, S; Kondo, S; Koyama, T; Sato, J; Shibaki, R; Shimizu, T; Shimomura, A; Sumino, S; Suri, A; Tamura, K; Yamamoto, N; Yonemori, K	1
Delaye, M; Rodrigues, M	1
Liu, MC; Sutedja, J; Tewari, KS	1
Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E	1
Gao, Y; Gong, Y; Jiang, X; Li, J; Luo, Y; Xie, C; Zeng, Z; Zhang, J; Zhang, N	1
Du, X; Hu, D; Jiang, L; Luo, S; Tang, W; Tang, Y; Zhao, G; Zhao, X	1
Ai, X; Chen, G; Cui, J; Ding, C; Dong, X; Gao, B; He, J; Hu, C; Hu, X; Huang, C; Jiang, L; Li, J; Li, X; Li, Y; Liao, W; Liu, A; Liu, C; Liu, X; Liu, Z; Lu, S; Ma, Z; Pan, Y; Shi, J; Song, Y; Wang, K; Wang, M; Wang, W; Xiong, J; Yang, N; Zhang, B; Zhang, D; Zhang, H; Zhang, X; Zhang, Y; Zhao, J; Zhou, J	1
Bahar, E; Kim, DC; Kim, HS; Kim, JY; Yoon, H	1
Chen, X; Cheng, X; Dai, Z; Gu, H; Guo, W; Ni, J; Wang, Y; Xu, X; Zhao, Q; Zhou, R	1
Guo, Q; Liu, L; Lu, W; Ma, Z; Sun, X; Wang, S; You, J; Zhang, Y; Zhao, Z	1
Distel, L; Fietkau, R; Gajdošová, F; Hecht, M; Jonuscheit, S; Jost, T; Wrobel, M	1
Chan, AL; Lang, HC; Leung, JH; Lo, HF; Wang, SY	1
Adam, V; Audeh, W; Balmaña, J; Cameron, DA; Colleoni, M; Ellard, SL; Erban, J; Goldstein, LJ; Goulioti, T; Honkoop, AH; Ignatiadis, M; Jen, KY; Johannsson, OT; Juan-Fita, MJ; Kaufman, B; Láng, I; Litière, S; Macpherson, IRJ; Mailliez, A; Manso, L; Musolino, A; Poncet, C; Razis, E; Trédan, O; Tryfonidis, K; Turner, NC; Tutt, AN; Vuylsteke, P; Zoppoli, G	1
Akce, M; Bacque, E; El-Khoueiry, A; Ewesuedo, R; Gupta, D; Judson, PL; Milton, A; O'Bryant, CL; Pan, P; Piha-Paul, SA; Tang, Y; Zajic, S; Zhang, ZY	1
Cai, Z; Cao, D; Chang, C; Jiang, Z; Liu, C; Mu, M; Shen, C; Yin, X; Yin, Y; Zhang, B; Zhang, L; Zhao, Z	1
Artali, R; Aviñó, A; Dallavalle, S; Eritja, R; Gargallo, R; Mattio, LM; Mazzini, S; Musso, L; Pisano, C; Princiotto, S	1
Baek, SH; Kim, BG; Lim, MC; Noh, JJ; Park, SY; Shin, W	1
Awad, MM; Dowlati, A; Dy, GK; Haque, B; Iannotti, N; Iyer Singh, N; Lu, S; Ramalingam, SS; Spigel, DR; Stinchcombe, TE; Tang, Y; Teslenko, I; Thara, E	1
Chen, L; Davidson, B; Hershman, DL; Moss, HA; Wright, JD	1
Hawkes, C; Hurteau, J; Liu, J; Maiese, EM; Spalding, C; Travers, K; Walder, L	1
Braicu, E; Carbone, V; Cibula, D; Colombo, N; Frenel, JS; Ghizzoni, V; Giolitto, S; Giudice, E; Lorusso, D; Musacchio, L; Perri, MT; Pignata, S; Ricci, C; Salutari, V; Scambia, G; Zagouri, F	1
Casey, PJ; Tang, J; Wang, M	1
Bu, H; Chu, R; Feng, J; Kong, B; Li, J; Li, X; Li, Y; Liu, L; Maurer, J; Meng, J; Pan, X; Peng, J; Song, K; Yao, S; Yuan, Z; Zhang, Q; Zhang, T	1
Lee, A	1
Bellesoeur, A; Beuzeboc, P; Diéras, V; Neuzillet, C; Rodrigues, M; Saint-Ghislain, M; Salaün, H; Stern, MH	1
Azaïs, H; Bats, AS; Bentivegna, E; Blons, H; Delanoy, N; Durdux, C; Koual, M; Laurent-Puig, P; Le Frère-Belda, MA; Le Gac, M; Nguyen-Xuan, HT; Perkins, G	1
Liu, M; Liu, T; Sun, L; Tan, S; Tang, J; Xiao, W; Zhou, X	1
Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J	1
Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F	1
Guan, W; Perez, JM; Thomas, SN; Twigg, CAI	1
Agouridis, AP; Mamais, I; Michalinos, A; Pagkali, A	1
Bach, R; Pesqué, D; Pujol, RM; Recuero-Borau, J; Tormo-Mainar, S	1
Chi, KN; Danila, DC; Efstathiou, E; Espina, BM; Fizazi, K; Francis, P; George, DJ; Lara, PN; Lopez-Gitlitz, A; Mason, GE; Olmos, D; Saad, F; Sandhu, S; Scher, HI; Smith, MR; Ståhl, O; Urtishak, KA; Yu, EY; Zhao, X	1
Bazan, F; Damerval, M; Hugues, M; Mayer, J; Omrani, S; Roux, MF	1
Bessudo, A; Dezube, BJ; Duncan, M; Evilevitch, L; Gabrail, N; Guo, W; Hamilton, E; Kumar, S; Lu, S; Patel, MR; Rodon, J; Sachdev, J; Yap, TA	1
Cui, Y; Du, F; Feng, L; Huang, W; Li, B; Yin, X	1
Bohrer, J; Damle, R; Driscoll, J; Fiorella, A; Hawkins, R; Mamidi, RNVS; Manning, CD; Packman, K; Patel, S; Snyder, LA; Stratton, CF; Tatikola, K; Tryputsen, V	1
Artioli, G; Baumann, K; Bradley, WH; Calvert, PM; Dørum, A; Forget, F; Fuentes, J; González-Martín, A; Gupta, D; Hietanen, S; Kumar, A; Levy, T; Li, Y; Malinowska, IA; McCormick, C; Monk, BJ; Moore, RG; O'Cearbhaill, RE; O'Malley, DM; Pérez-Fidalgo, JA; Selle, F; Shahin, MS; Slomovitz, BM; Tusquets, I; Vulsteke, C	1
Asano, H; Enomoto, T; Ito, YM; Matsumura, N; Oda, K; Shimada, M; Watari, H; Yoshihara, K	1
Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M	1
Belotte, J; Clements, A; Fleming, EL; Gray, HJ; Gupta, D; Hamilton, E; Hardesty, MM; Keeton, EK; Konecny, GE; Krivak, TC; Moore, RG; Richardson, DL; Wang, P; Wright, GS	1
Feng, Y; Jia, H; Jiang, R; Jiang, W; Liu, J; Shi, T; Teng, Y; Wang, H; Wang, X; Wu, S; Xiang, L; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y	1
Ellisen, LW; Graham, JR; Hamilton, E; Han, H; Hazard, S; Irie, H; Isakoff, SJ; Liu, MC; Pan, P; Reeves, J; Santa-Maria, CA; Shan, M; Spring, LM; Tang, Y	1
González-Martín, A; Gupta, D; Korach, J; Lechpammer, S; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Wu, X; York, W	1
Domchek, SM; Donze, A; Gosselin, MK; Karasic, T; Massa, R; Mick, R; O'Hara, M; Onyiah, C; Reiss, KA; Schneider, C; Teitelbaum, U; Tondon, R; Vonderheide, RH	1
Barquin, A; Churruca, C; Constenla, M; Cueva, JF; de Juan, A; Estévez, P; Fernández, I; Gallego, A; García, Y; González-Martín, A; Guerra, E; Herrero, A; Juárez, A; Legerén, M; Manso, L; Marquina, G; Martín, C; Martín, T; Martínez Bueno, A; Maximiano, C; Palacio, I; Pardo, B; Quindós, M; Sánchez, L; Santaballa, A; Yubero, A	1
Buckley, L; González-Martin, A; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Rimel, BJ; Wu, X	1
Frumovitz, M; Plante, M; St-Gelais, J; Touhami, O	1
Chen, X; Cheng, X; Huang, X; Ju, X; Li, J; Li, Z; Liu, F; Shou, H; Tang, J; Tang, X; Wang, H; Wen, H; Wu, X; Yang, H; Yang, J; Zhang, L; Zhang, M; Zheng, F	1
Baumann, K; Baurain, JF; Calvert, PM; Denys, H; Follana, P; Gaba, L; Ghamande, SA; González-Martín, A; Graybill, WS; Guerra, EM; Gupta, D; Korach, J; Li, Y; Malinowska, IA; Mirza, MR; Monk, BJ; O'Malley, DM; Pisano, C; Prendergast, E; Rose, PG; Stephanie Yap, OW	1
Ikeda, Y; Kajiyama, H; Nei, T; Niimi, K; Tamauchi, S; Yoshikawa, N	1
Bjartell, A; Sjöström, M	1
Backes, F; Compton, N; Freyer, G; González-Martín, A; Graybill, W; Heitz, F; Lorusso, D; Malinowska, IA; McCormick, CC; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Shtessel, L; Vergote, I; Vulsteke, C	1
Cai, H; Cui, H; Hang, W; Hao, M; Hou, J; Huang, Y; Kong, B; Li, G; Li, N; Lin, A; Liu, J; Liu, Z; Lou, G; Lu, W; Pan, L; Pan, Y; Qu, P; Wang, C; Wang, J; Wang, K; Wang, L; Wu, L; Wu, X; Yang, H; Yang, Y; Yao, S; Yin, R; Zhang, Y; Zhao, H; Zhen, X; Zheng, H; Zhu, J; Zou, D	1
Ngan, RKC	1
Hashimoto, K; Kanao, H; Kawakami, K; Mori, Y; Shibata, N; Shimizu, H; Soejima, A; Sugisaki, T; Yamaguchi, M; Yokokawa, T; Yunokawa, M	1
Chen, B; Chen, J; He, A; Hou, W; Jia, M; Jiang, Z; Li, M; Miao, P; Qiu, S; Shao, Z; Shen, Y; Sun, W; Wu, X; Xu, J; Xu, X; Yuan, D; Zhang, B; Zhang, Y; Zhao, M; Zhou, Y; Zhu, T; Zhu, Y	1
Adams, S; Baines, A; Chon, HS; Cloven, NG; Coleman, RL; Dalton, H; Duska, LR; ElNaggar, AC; Gaillard, S; Holloway, RW; Huang, M; Konstantinopoulos, PA; Monk, BJ; Nelsen, LM; O'Cearbhaill, RE; O'Malley, DM; Randall, LM; Samnotra, V; Striha, A; Tarkar, A; Waggoner, S	1

Reviews

31 review(s) available for indazoles and niraparib

Article	Year
PARP inhibitors in ovarian cancer: current status and future promise. Gynecologic oncology, 2014, Volume: 133, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2014
[Cancer therapy by PARP inhibitors]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Enzyme Inhibitors; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Mutation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair	2015
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecologic oncology, 2018, Volume: 149, Issue:1 Topics: Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2018
Update on PARP Inhibitors in Breast Cancer. Current treatment options in oncology, 2018, 04-11, Volume: 19, Issue:5 Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival	2018
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer treatment reviews, 2018, Volume: 67 Topics: Benzamides; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms	2018
The role of niraparib for the treatment of ovarian cancer. Future oncology (London, England), 2018, Volume: 14, Issue:25 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Mutation; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
Niraparib for the treatment of ovarian cancer. Expert review of anticancer therapy, 2018, Volume: 18, Issue:8 Topics: Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Practice Guidelines as Topic	2018
Niraparib: A Review in Ovarian Cancer. Targeted oncology, 2018, Volume: 13, Issue:4 Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Journal of geriatric oncology, 2019, Volume: 10, Issue:2 Topics: Aged; Aged, 80 and over; Breast Neoplasms; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations	2019
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Current treatment options in oncology, 2018, 11-15, Volume: 19, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:4 Topics: Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2019
A decade of clinical development of PARP inhibitors in perspective. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 09-01, Volume: 30, Issue:9 Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genomic Instability; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors	2019
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current drug targets, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2020
Latest clinical evidence of maintenance therapy in ovarian cancer. Current opinion in obstetrics & gynecology, 2020, Volume: 32, Issue:1 Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic	2020
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The Annals of pharmacotherapy, 2020, Volume: 54, Issue:10 Topics: Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2020
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs, 2020, Volume: 80, Issue:15 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Maintenance Chemotherapy; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Randomized Controlled Trials as Topic; Recombinational DNA Repair; United States; United States Food and Drug Administration	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. British journal of cancer, 2021, Volume: 124, Issue:3 Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Clinical Trials as Topic; DNA Damage; DNA Repair; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; High-Throughput Nucleotide Sequencing; Humans; Immune Checkpoint Inhibitors; Indazoles; Indoles; Male; Phthalazines; Piperazines; Piperidines; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Prognosis; Prostatic Neoplasms	2021
PARP Inhibitors in Prostate Cancer. Anticancer research, 2021, Volume: 41, Issue:2 Topics: Animals; BRCA1 Protein; BRCA2 Protein; Genetic Predisposition to Disease; Humans; Indazoles; Indoles; Male; Mutation; Neoplasm Metastasis; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Treatment Outcome	2021
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecologic oncology, 2021, Volume: 162, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Humans; Incidence; Indazoles; Neoplasms; Phthalazines; Piperazines; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Time Factors	2021
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. Pharmacological research, 2021, Volume: 172 Topics: Humans; Indazoles; Indoles; Neoplasms; Network Meta-Analysis; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic	2021
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer. Targeted oncology, 2021, Volume: 16, Issue:6 Topics: Adult; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines	2021
[Homologous recombination deficiency and PARP inhibitors in therapeutics]. Bulletin du cancer, 2022, Volume: 109, Issue:1 Topics: Breast Neoplasms; DNA Damage; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Indoles; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Recombinational DNA Repair	2022
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers]. Bulletin du cancer, 2022, Volume: 109, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; DNA Damage; DNA Repair-Deficiency Disorders; Endometrial Neoplasms; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Papillomavirus Infections; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Uterine Cervical Neoplasms	2022
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer. Bulletin du cancer, 2021, Volume: 108, Issue:9S1 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. Current oncology (Toronto, Ont.), 2022, 01-12, Volume: 29, Issue:1 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines	2022
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). Journal of gynecologic oncology, 2022, Volume: 33, Issue:4 Topics: Clinical Trials, Phase II as Topic; Female; Genital Neoplasms, Female; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2022
Niraparib treatment for patients with Future oncology (London, England), 2022, Volume: 18, Issue:23 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2022
Safety and management of niraparib monotherapy in ovarian cancer clinical trials. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023, 06-05, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2023
First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two 'long responder' case reports and review of the current literature. The Journal of international medical research, 2023, Volume: 51, Issue:9 Topics: Asian People; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2023

Trials

38 trial(s) available for indazoles and niraparib

Article	Year
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Cohort Studies; Female; Follow-Up Studies; Heterozygote; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Prostatic Neoplasms; Tissue Distribution	2013
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England journal of medicine, 2016, 12-01, Volume: 375, Issue:22 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Disease-Free Survival; Double-Blind Method; Female; Genes, BRCA1; Germ-Line Mutation; Homologous Recombination; Humans; Indazoles; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Platinum Compounds; Young Adult	2016
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Breast Neoplasms; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Radioactive Tracers; Tandem Mass Spectrometry	2018
Safety and dose modification for patients receiving niraparib. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 08-01, Volume: 29, Issue:8 Topics: Administration, Oral; Adult; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Incidence; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platelet Count; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Retrospective Studies; Risk Factors; Thrombocytopenia	2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. The Lancet. Oncology, 2018, Volume: 19, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Piperidines; Progression-Free Survival; Quality of Life; Surveys and Questionnaires	2018
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic oncology, 2019, Volume: 152, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2019
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:4 Topics: Aged; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Double-Blind Method; Electrocardiography; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Long QT Syndrome; Middle Aged; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 2019, Volume: 20, Issue:5 Topics: Adolescent; Adult; Aged; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Time Factors; United States; Young Adult	2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 11-10, Volume: 37, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2019
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2019
Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer. The oncologist, 2020, Volume: 25, Issue:1 Topics: Female; Humans; Indazoles; Male; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Disease Progression; Female; Humans; Hypertension; Indazoles; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Proteinuria; Thrombocytopenia	2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England journal of medicine, 2019, 12-19, Volume: 381, Issue:25 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Nausea; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality of Life; Survival Analysis	2019
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature communications, 2020, 03-19, Volume: 11, Issue:1 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CD8-Positive T-Lymphocytes; DNA Mutational Analysis; Drug Monitoring; Female; Gene Amplification; Humans; Indazoles; Interferons; Macrophages; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Recombinational DNA Repair; Single-Cell Analysis; Treatment Outcome; Tumor Microenvironment	2020
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of gynecologic oncology, 2020, Volume: 31, Issue:3 Topics: Adolescent; China; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Positron Emission Tomography Computed Tomography; Quality of Life	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rati Clinical lung cancer, 2021, Volume: 22, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; DNA Repair Enzymes; Germ-Line Mutation; Humans; Indazoles; Lung Neoplasms; Mesothelioma, Malignant; Mutation; Piperidines; Pleural Neoplasms; Prognosis; Prospective Studies	2021
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecologic oncology, 2020, Volume: 159, Issue:2 Topics: Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2020
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021, Volume: 31, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors	2021
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Journal of gynecologic oncology, 2021, Volume: 32, Issue:2 Topics: Female; Homologous Recombination; Humans; Indazoles; Japan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. Journal of gynecologic oncology, 2021, Volume: 32, Issue:2 Topics: Female; Humans; Indazoles; Japan; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines	2021
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Japanese journal of clinical oncology, 2021, Apr-30, Volume: 51, Issue:5 Topics: Adult; Aged; Cohort Studies; Female; Humans; Indazoles; Japan; Male; Middle Aged; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins	2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines	2021
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:5 Topics: Aged; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Liver; Male; Middle Aged; Piperidines	2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer, 2022, Jan-01, Volume: 128, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2022
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021, Volume: 31, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. Journal of gynecologic oncology, 2022, Volume: 33, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea	2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:3 Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; Humans; Indazoles; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia	2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Humans; Indazoles; Neoplasms; Paclitaxel; Piperidines; Vascular Endothelial Growth Factor A	2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecologic oncology, 2022, Volume: 166, Issue:1 Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Piperidines	2022
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecologic oncology, 2022, Volume: 166, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Platinum	2022
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hypertension; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Nivolumab; Pancreatic Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors	2022
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Cancer, 2023, 06-15, Volume: 129, Issue:12 Topics: Body Weight; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prospective Studies	2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. European journal of cancer (Oxford, England : 1990), 2023, Volume: 189 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Progression-Free Survival	2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology, 2023, 09-01, Volume: 9, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Progression-Free Survival	2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). Gynecologic oncology, 2023, Volume: 178 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2023

Other Studies

105 other study(ies) available for indazoles and niraparib

Article	Year
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. Journal of medicinal chemistry, 2009, Nov-26, Volume: 52, Issue:22 Topics: Administration, Oral; Amides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Discovery; Drug Stability; Enzyme Inhibitors; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Inhibitory Concentration 50; Mutation; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats	2009
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Burden; Xenograft Model Antitumor Assays	2012
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer research, 2013, Volume: 33, Issue:3 Topics: Animals; Caspase 3; Cell Line, Tumor; Chemoradiotherapy; Enzyme Inhibitors; Female; Histones; Humans; Indazoles; Mice; Neoplasm Metastasis; Neuroblastoma; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents	2013
PARP inhibitors: pitfalls and promises. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: BRCA1 Protein; BRCA2 Protein; Female; Humans; Indazoles; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene, 2013, Nov-21, Volume: 32, Issue:47 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; High-Throughput Screening Assays; Humans; Indazoles; Lung Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Isoforms; Rad51 Recombinase; RNA Interference; RNA, Small Interfering	2013
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget, 2014, Jul-15, Volume: 5, Issue:13 Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Histones; Humans; Hydrogen Peroxide; Indazoles; Lung Neoplasms; Male; Microscopy, Fluorescence; Oxidants; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Rad51 Recombinase; Radiation-Sensitizing Agents; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	2014
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. Journal of medicinal chemistry, 2015, Apr-23, Volume: 58, Issue:8 Topics: Animals; BRCA1 Protein; BRCA2 Protein; Drug Discovery; Enzyme Inhibitors; Homologous Recombination; Humans; Indazoles; Models, Molecular; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2015
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Molecular cancer research : MCR, 2015, Volume: 13, Issue:11 Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Tolerance; Humans; Indazoles; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2015
Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular cancer therapeutics, 2015, Volume: 14, Issue:11 Topics: Animals; Astrocytoma; Benzimidazoles; Blotting, Western; Brain Stem Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Child; Combined Modality Therapy; Glioma; Humans; Indazoles; Kaplan-Meier Estimate; Linear Models; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pons; Radiotherapy; Xenograft Model Antitumor Assays	2015
PARPs pick-up. Nature reviews. Drug discovery, 2016, Jul-29, Volume: 15, Issue:8 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Industry; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic oncology, 2016, Volume: 143, Issue:2 Topics: DNA-Binding Proteins; Female; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic	2016
Niraparib Slows Ovarian Cancer Progression. Cancer discovery, 2016, Volume: 6, Issue:12 Topics: BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Disease Progression; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome	2016
Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017, Jan-01, Volume: 1040 Topics: Chromatography, High Pressure Liquid; Humans; Indazoles; Limit of Detection; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Tandem Mass Spectrometry	2017
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Benzimidazoles; Enzyme Inhibitors; HEK293 Cells; Humans; Indazoles; Models, Molecular; Phenanthrenes; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tankyrases	2017
Niraparib: First Global Approval. Drugs, 2017, Volume: 77, Issue:9 Topics: Adult; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Approval; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration	2017
[Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.] Recenti progressi in medicina, 2017, Volume: 108, Issue:6 Topics: Antineoplastic Agents; Disease-Free Survival; DNA Breaks, Double-Stranded; DNA Repair; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2017
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:4 Topics: Cell Line, Tumor; Clone Cells; DNA Repair; Humans; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Phthalazines; Piperazines; Piperidines; Pleural Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Tumor Suppressor Proteins; Ubiquitin Thiolesterase	2017
PARP inhibitors for ovarian cancer. The Medical letter on drugs and therapeutics, 2017, 12-04, Volume: 59, Issue:1535 Topics: Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome	2017
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:3 Topics: Adult; Aged; Area Under Curve; Dietary Fats; Drug Monitoring; Fasting; Female; Food-Drug Interactions; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Therapeutic Equivalency	2018
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. Cancer biology & therapy, 2018, 06-03, Volume: 19, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinolines	2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-01, Volume: 24, Issue:17 Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment	2018
PARPi related toxicities: do we need more appropriate instruments to evaluate it? Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 08-01, Volume: 29, Issue:8 Topics: Humans; Indazoles; Piperidines	2018
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine	2018
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-01, Volume: 24, Issue:17 Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors	2018
Valproate augments Niraparib killing of tumor cells. Cancer biology & therapy, 2018, Volume: 19, Issue:9 Topics: Animals; Autophagy; Biomarkers; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gene Knockdown Techniques; Humans; Indazoles; Mice; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Signal Transduction; Valproic Acid	2018
PARP inhibitors and quality of life in ovarian cancer. The Lancet. Oncology, 2018, Volume: 19, Issue:8 Topics: Double-Blind Method; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2018
Using PARP Inhibitors in Advanced Ovarian Cancer. Oncology (Williston Park, N.Y.), 2018, 07-15, Volume: 32, Issue:7 Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting	2018
Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2019, Jan-05, Volume: 206 Topics: Humans; Indazoles; Molecular Docking Simulation; Piperidines; Protein Binding; Serum Albumin, Human; Spectrometry, Fluorescence; Static Electricity	2019
Niraparib - A promising drug with hematological toxicity. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:7 Topics: Aged, 80 and over; Female; Hematologic Diseases; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2019
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma Cancer research, 2018, 12-15, Volume: 78, Issue:24 Topics: Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Cycle; Cell Line, Tumor; Chemoprevention; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA Repair; Female; Germ-Line Mutation; HeLa Cells; Humans; Indazoles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Synthetic Lethal Mutations; X-ray Repair Cross Complementing Protein 1	2018
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. British journal of cancer, 2018, Volume: 119, Issue:11 Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Heterografts; Humans; Indazoles; Mutation; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. PharmacoEconomics, 2019, Volume: 37, Issue:3 Topics: Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States	2019
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:12 Topics: Clinical Decision-Making; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States	2018
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of medical economics, 2019, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States	2019
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Scientific reports, 2019, 02-12, Volume: 9, Issue:1 Topics: Animals; Antibodies; Base Sequence; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Gene Expression Profiling; Humans; Immunotherapy; Indazoles; Interferons; Mice; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Receptor	2019
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic oncology, 2019, Volume: 152, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Indazoles; Indoles; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic	2019
Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet? The Lancet. Oncology, 2019, Volume: 20, Issue:5 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2019
Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". PharmacoEconomics, 2019, Volume: 37, Issue:7 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2019
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'. PharmacoEconomics, 2019, Volume: 37, Issue:7 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2019
Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". PharmacoEconomics, 2019, Volume: 37, Issue:8 Topics: Cost-Benefit Analysis; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2019
Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma. Carcinogenesis, 2020, 05-14, Volume: 41, Issue:3 Topics: Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Chloroquine; Drug Synergism; Gene Expression Regulation, Neoplastic; Heterografts; Histones; Humans; Indazoles; Liver Neoplasms; Mice; Oncogene Protein v-akt; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; TOR Serine-Threonine Kinases	2020
Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular carcinogenesis, 2019, Volume: 58, Issue:10 Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indazoles; Indoles; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Wnt Signaling Pathway	2019
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ case reports, 2019, Aug-28, Volume: 12, Issue:8 Topics: Aged; Brain Neoplasms; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Treatment Outcome	2019
Chemotherapy-free, but not quite free chemotherapy. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum	2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 12-01, Volume: 37, Issue:34 Topics: BRCA1 Protein; BRCA2 Protein; Disease Progression; Drug Administration Schedule; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors	2019
Highly enantioselective rhodium-catalyzed cross-coupling of boronic acids and racemic allyl halides. Nature protocols, 2019, Volume: 14, Issue:10 Topics: Allyl Compounds; Boronic Acids; Catalysis; Chemistry Techniques, Synthetic; Indazoles; Piperidines; Rhodium; Stereoisomerism	2019
Niraparib improves progression-free survival in ovarian cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:11 Topics: Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic	2019
Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma. Applied microbiology and biotechnology, 2019, Volume: 103, Issue:23-24 Topics: Autophagic Cell Death; Cell Cycle; Cell Line, Tumor; DNA Damage; Humans; Indazoles; Laryngeal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2019
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer, 2020, 02-15, Volume: 126, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Xenograft Model Antitumor Assays	2020
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:12 Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum	2019
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer. The New England journal of medicine, 2019, 12-19, Volume: 381, Issue:25 Topics: Cystadenocarcinoma, Serous; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Precision Medicine	2019
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply. JAMA oncology, 2020, 03-01, Volume: 6, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Indazoles; Mutation; Ovarian Neoplasms; Piperidines; Recombinational DNA Repair	2020
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab. JAMA oncology, 2020, 03-01, Volume: 6, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Mutation; Piperidines; Recombinational DNA Repair; Triple Negative Breast Neoplasms	2020
[PARP inhibitors in first-line of ovarian cancers]. Bulletin du cancer, 2020, Volume: 107, Issue:1 Topics: Benzimidazoles; Clinical Trials as Topic; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific reports, 2020, 02-17, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Dyrk Kinases; HEK293 Cells; Humans; Indazoles; Indoles; Isoenzymes; Molecular Docking Simulation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polypharmacology; Protein Binding; Protein Interaction Domains and Motifs; Protein Serine-Threonine Kinases; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Substrate Specificity	2020
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. International journal of radiation biology, 2021, Volume: 97, Issue:8 Topics: Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; Head and Neck Neoplasms; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazoles; Pyrimidinones; Radiation Tolerance	2021
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecologic oncology, 2020, Volume: 157, Issue:2 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indazoles; Indoles; Infusions, Intravenous; Markov Chains; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; United States	2020
PARP Inhibitors in Ovarian Cancer. The New England journal of medicine, 2020, 04-16, Volume: 382, Issue:16 Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report. BMC psychiatry, 2020, 04-15, Volume: 20, Issue:1 Topics: Anxiety; Depression; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells. Head & neck, 2020, Volume: 42, Issue:9 Topics: Cell Line, Tumor; Head and Neck Neoplasms; Humans; Indazoles; Photons; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protons; Radiation-Sensitizing Agents	2020
Involvement of POLA2 in Double Strand Break Repair and Genotoxic Stress. International journal of molecular sciences, 2020, Jun-15, Volume: 21, Issue:12 Topics: Brain Neoplasms; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Damage; DNA Polymerase I; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Glioma; Humans; Indazoles; Piperidines; Radiation, Ionizing; Survival Analysis; Up-Regulation	2020
Nephrotoxicity Associated With Niraparib. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 76, Issue:6 Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Diseases; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Risk Factors	2020
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:10 Topics: Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years	2020
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts. BMC cancer, 2020, Aug-18, Volume: 20, Issue:1 Topics: Apoptosis; Cell Survival; Chemoradiotherapy; Drug Interactions; Fibroblasts; G2 Phase Cell Cycle Checkpoints; Homologous Recombination; Humans; Indazoles; Melanoma; Phthalazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Primary Cell Culture; Skin; Skin Neoplasms; Tumor Cells, Cultured	2020
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecologic oncology, 2020, Volume: 159, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community Health Centers; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Female; Follow-Up Studies; Gynecology; Humans; Indazoles; Indoles; Medical Oncology; Medication Therapy Management; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Workload	2020
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future oncology (London, England), 2020, Volume: 16, Issue:33 Topics: Fallopian Tube Neoplasms; Female; Humans; Indazoles; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Treatment Outcome	2020
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo. Nucleic acids research, 2020, 09-25, Volume: 48, Issue:17 Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; DNA Damage; DNA Repair; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; Humans; Indazoles; Kinetics; Molecular Imaging; NAD; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinant Proteins; X-ray Repair Cross Complementing Protein 1	2020
Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. The American journal of case reports, 2020, Nov-16, Volume: 21 Topics: Adenosine Diphosphate Ribose; Breast Neoplasms; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Thiazoles; Thiophenes; Thrombocytopenia	2020
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. JAMA network open, 2020, 12-01, Volume: 3, Issue:12 Topics: Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Ovarian Epithelial; Computing Methodologies; Cost-Benefit Analysis; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Maintenance Chemotherapy; Medicare; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2020
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of experimental & clinical cancer research : CR, 2021, Jan-06, Volume: 40, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Humans; Indazoles; Irinotecan; Mice; Mice, Nude; Mutation; Piperidines	2021
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs. Nature communications, 2021, 02-02, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzimidazoles; Binding Sites; Carrier Proteins; Catalysis; Catalytic Domain; DNA Repair Enzymes; Humans; Indazoles; Indoles; Nuclear Proteins; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Protein Binding	2021
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report. Annals of palliative medicine, 2021, Volume: 10, Issue:1 Topics: Brain Neoplasms; China; Endometrial Neoplasms; Female; Humans; Indazoles; Middle Aged; Piperidines	2021
How to start niraparib in real-world Asian ovarian cancer patients? Journal of gynecologic oncology, 2021, Volume: 32, Issue:2 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2021
[New drug approval: Olaparib and niraparib - first line in ovarian cancer]. Bulletin du cancer, 2021, Volume: 108, Issue:4 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Female; Humans; Indazoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy. Expert review of anticancer therapy, 2021, Volume: 21, Issue:5 Topics: Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2021
PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:9 Topics: Animals; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL5; Chemokine CXCL10; Chemoradiotherapy; DNA Breaks, Double-Stranded; Female; Fluorescent Antibody Technique; Genes, erbB-1; Humans; Immune System; Immunocompetence; Indazoles; Interferon Regulatory Factor-3; Interferon-beta; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation; Nuclear Proteins; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Real-Time Polymerase Chain Reaction; TATA Box Binding Protein-Like Proteins; Tumor Stem Cell Assay	2021
NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation. Experimental cell research, 2021, 06-15, Volume: 403, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atlases as Topic; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Databases, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NEDD8 Protein; Piperidines; Prostatic Neoplasms, Castration-Resistant; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays	2021
Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. International journal of molecular sciences, 2021, Apr-10, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Humans; Indazoles; Mitochondria; Nuclear Proteins; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Signal Transduction; Synthetic Lethal Mutations; Twist-Related Protein 1	2021
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. Journal of ovarian research, 2021, May-17, Volume: 14, Issue:1 Topics: Adult; Aged; China; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. Genes, 2021, 05-31, Volume: 12, Issue:6 Topics: Cell Cycle; Cell Line, Tumor; Fibroblasts; Humans; Indazoles; Melanoma; Phthalazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Tolerance	2021
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:3 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines	2022
Niraparib for Advanced Breast Cancer with Germline Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 10-15, Volume: 27, Issue:20 Topics: BCG Vaccine; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Germ Cells; Germ-Line Mutation; Humans; Indazoles; Nitriles; Piperidines	2021
Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region. International journal of molecular sciences, 2021, Aug-14, Volume: 22, Issue:16 Topics: Benzimidazoles; DNA; G-Quadruplexes; Humans; Indazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic	2021
Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. Anticancer research, 2021, Volume: 41, Issue:9 Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Tapering; Feasibility Studies; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Outcome	2021
Adherence to PARP inhibitor therapy among women with ovarian cancer. Gynecologic oncology, 2021, Volume: 163, Issue:2 Topics: Female; Humans; Indazoles; Medication Adherence; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies	2021
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective. Journal of managed care & specialty pharmacy, 2021, Volume: 27, Issue:10 Topics: Adult; Aged; Budgets; Cost-Benefit Analysis; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States	2021
Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair. Life science alliance, 2021, Volume: 4, Issue:12 Topics: Animals; Apoptosis; Benzamides; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Female; Genetic Vectors; HEK293 Cells; Humans; Indazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Methyltransferases; Ribonucleosides; RNA, Small Interfering; Tumor Burden; Xenograft Model Antitumor Assays	2021
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. Journal of translational medicine, 2021, 10-07, Volume: 19, Issue:1 Topics: B7-H1 Antigen; Female; Humans; Immunity; Indazoles; Ovarian Neoplasms; Piperidines	2021
Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer. Experimental cell research, 2022, 01-15, Volume: 410, Issue:2 Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Models, Biological; Ovarian Neoplasms; Piperidines; Platinum; Stress, Psychological	2022
Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells. Journal of the American Society for Mass Spectrometry, 2022, Feb-02, Volume: 33, Issue:2 Topics: Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Indoles; Mass Spectrometry; Mitochondria; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Proteomics; Signal Transduction	2022
Switching PARP inhibitors as an effective approach for niraparib-induced erythema multiforme. International journal of dermatology, 2022, Volume: 61, Issue:10 Topics: Erythema Multiforme; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2022
Pancytopenia in a patient treated with fusidic acid and niraparib: a case report. European journal of hospital pharmacy : science and practice, 2023, Volume: 30, Issue:5 Topics: Anti-Bacterial Agents; Fusidic Acid; Humans; Indazoles; Pancytopenia	2023
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:8 Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents	2022
Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. Molecular cancer therapeutics, 2022, 07-05, Volume: 21, Issue:7 Topics: Animals; Bone Neoplasms; Humans; Indazoles; Male; Mice; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostate; Prostatic Neoplasms; Tissue Distribution	2022
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy. International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:8 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors	2022
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of gynecologic oncology, 2022, Volume: 33, Issue:4 Topics: Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2022
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature cancer, 2022, Volume: 3, Issue:8 Topics: Breast Neoplasms; Female; Humans; Indazoles; Neoadjuvant Therapy; Pilot Projects; Piperidines	2022
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. European journal of cancer (Oxford, England : 1990), 2023, Volume: 182 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors	2023
Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023, 04-03, Volume: 33, Issue:4 Topics: Carcinoma, Neuroendocrine; Cervix Uteri; Female; Humans; Indazoles; Nivolumab; Uterine Cervical Neoplasms	2023
Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China. Cancer communications (London, England), 2023, Volume: 43, Issue:6 Topics: China; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2023
Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. The journal of obstetrics and gynaecology research, 2023, Volume: 49, Issue:7 Topics: BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms	2023
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer. European urology, 2023, Volume: 84, Issue:4 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Piperidines; Prednisone; Prostatic Neoplasms, Castration-Resistant	2023
Niraparib/abiraterone acetate (Akeega) for prostate cancer. The Medical letter on drugs and therapeutics, 2023, 09-04, Volume: 65, Issue:1684 Topics: Abiraterone Acetate; Humans; Indazoles; Male; Piperidines; Prostatic Neoplasms	2023
Serum Creatinine Elevation as a Risk Factor for Niraparib-induced Hematologic Toxicity. Anticancer research, 2023, Volume: 43, Issue:10 Topics: Anemia; Creatinine; Female; Humans; Indazoles; Neutropenia; Ovarian Neoplasms; Risk Factors; Thrombocytopenia	2023
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China. Targeted oncology, 2023, Volume: 18, Issue:6 Topics: Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines	2023